Starting from April 1, 2026, China's National Medical Products Administration (NMPA) will classify radiofrequency (RF) beauty devices, including RF therapy and skin treatment devices, as Class III medical equipment. Products without valid NMPA registration certificates will be prohibited from production, import, and sale. This policy directly impacts overseas suppliers and importers, as shipments without proper certification may face customs clearance issues, including potential rejection or destruction.

Event Overview

Effective April 1, 2026, RF beauty devices will be subject to stricter regulatory oversight in China. The NMPA mandates that all such devices must obtain Class III medical equipment registration before entering the market. Non-compliant products in transit or newly ordered will be intercepted by Chinese customs, while already imported devices lacking certification may require return or disposal.

Industries Affected

Overseas Manufacturers and Exporters

Companies producing RF beauty devices for the Chinese market must now secure NMPA registration, which involves rigorous testing and documentation. Failure to comply will block market entry.

Importers and Distributors

Businesses importing or distributing these devices must verify suppliers' NMPA certificates. Unregistered inventory risks being held at customs or recalled.

E-commerce and Retail Platforms

Online and offline sellers need to ensure product compliance to avoid penalties. Platforms may need to update listing requirements and vetting processes.

Key Actions for Businesses

Verify Certification Status

Importers should immediately check whether their suppliers have obtained or applied for NMPA registration. For pending orders, confirm certification timelines.

Assess In-Transit Inventory

Evaluate current shipments scheduled to arrive after April 2026. Explore options for certification applications or alternative markets if registration is unattainable.

Update Compliance Protocols

Strengthen supply chain due diligence by incorporating NMPA registration checks into procurement procedures. Consider contractual protections for certification delays.

Industry Perspective

This move reflects China's tightening oversight of aesthetic medical devices. While it raises compliance costs, it also standardizes a previously ambiguous market segment. The regulation may reshape competitive dynamics, favoring established manufacturers with regulatory experience. Companies should treat this as an urgent operational priority rather than a distant compliance matter.

Conclusion

The NMPA's reclassification signals a maturing regulatory environment for beauty devices in China. Businesses must act decisively to adapt their China market strategies, prioritizing certification readiness and supply chain adjustments. Proactive engagement with regulatory consultants is advisable to navigate the complex approval process.

Source

National Medical Products Administration (NMPA) official announcement